ProSomnus, maker of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) stated the company is “well-positioned” to support patients with OSA and sleep physicians who can no longer access discontinued CPAP devices. 

Last week, Philips Respironics announced the discontinuation of many devices used for the treatment and diagnosis of sleep apnea, including CPAP systems. 

“We expect that this Philips discontinuation is likely to create a supply chain issue with CPAP availability and affect access to care. ProSomnus is positioned to provide patients timely access to care with its clinically proven and patient preferred precision appliances,” says Mark T. Murphy, DDS D-ABDSM, lead clinical faculty for ProSomnus and owner of dental sleep practice Funktional Sleep in Rochester Hills, Mich.

ProSomnus precision intraoral devices have demonstrated excellent efficacy, adherence, and patient preference in numerous clinical studies, including a head-to-head cross-over study comparing the effectiveness of treatment with ProSomnus devices versus CPAP devices, the company notes in a release. 

“Oral appliance therapy has been demonstrated in clinical studies to be highly effective in managing sleep disorders, offering patients a non-invasive and comfortable alternative to traditional CPAP therapy. I encourage patients and healthcare providers to explore all treatment options for OSA,” says Stacey Layman, D-ABDSM, D-ABSA, in a release. 

ProSomnus notes that it is generally able to connect sleep physicians with local providers who are in-network with medical insurance, take Medicare, and have demonstrated strong results and high levels of patient satisfaction.

“With this announcement by Philips Respironics, I believe that the public in need of treatment for OSA is becoming more disenfranchised,” says Kent Smith, D-ABDSM, ASBA, in a release. “It is past the time for the PAP community of healthcare providers to partner with qualified dental sleep medicine providers to facilitate a less restrictive avenue for treatment. We will hear of stricter allocation of PAP units soon, and I believe it would benefit the patients needing help to be provided with other options.”